Jamie A. Love-Nichols

Jamie A. Love-Nichols

Auto-generated profile, based on publicly available information

Jamie A. Love-Nichols

Translational Neuroscience Center, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
SSSiddharth Srivastava
Siddharth Srivastava
JLJamie A. Love-Nichols
Jamie A. Love-Nichols
KDKira A. Dies
Kira A. Dies
DLDavid H. Ledbetter
David H. Ledbetter
CMChrista L. Martin
Christa L. Martin
DMDavid Miller
David Miller
Purpose For neurodevelopmental disorders (NDDs), etiological evaluation can be a diagnostic odyssey involving numerous genetic tests, underscoring the need to develop a streamlined algorithm maximizing molecular diagnostic yield for this clinical indication. Our objective was to compare the yield of exome sequencing (ES) with that of chromosomal microarray (CMA), the current first-tier test for NDDs. Methods We performed a PubMed scoping review and meta-analysis investigating the diagnostic yield of ES for NDDs as the basis of a consensus development conference. We defined NDD as global developmental delay, intellectual disability, and/or autism spectrum disorder. The consensus development conference included input from genetics professionals, pediatric neurologists, and developmental behavioral pediatricians. Results After applying strict inclusion/exclusion criteria, we identified 30 articles with data on molecular diagnostic yield in individuals with isolated NDD, or NDD plus associated conditions (such as Rett-like features). Yield of ES was 36% overall, 31% for isolated NDD, and 53% for the NDD plus associated conditions. ES yield for NDDs is markedly greater than previous studies of CMA (15–20%). Conclusion Our review demonstrates that ES consistently outperforms CMA for evaluation of unexplained NDDs. We propose a diagnostic algorithm placing ES at the beginning of the evaluation of unexplained NDDs.

29 July 2020 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
SSSiddharth Srivastava
Siddharth Srivastava
JLJamie A. Love-Nichols
Jamie A. Love-Nichols
KDKira A. Dies
Kira A. Dies
DLDavid H. Ledbetter
David H. Ledbetter
CMChrista L. Martin
Christa L. Martin
DMDavid Miller
David Miller
An amendment to this paper has been published and can be accessed via a link at the top of the paper.